Epilepsy generic expansion Opportunity to engage Solaris Pharma on expanding their generic epileptic portfolio beyond brivaracetam by identifying other high-value branded-to-generic substitutions in CNS or neurology, leveraging their expertise in complex formulations and regulatory strategy.

Dermatology and sterile Target partnerships for Solaris to co-develop or scale sterile and dermatological products, aligning with their stated pipeline growth in sterile and dermatology to access markets requiring specialized manufacturing capabilities.

Early access advantage Position Solaris as a partner for early access programs and rapid development timelines to bring challenging high-value generics to market, offering speed-to-market benefits to healthcare systems and wholesalers.

Integrated development Leverage Solaris’ integrated R&D Regulatory and Commercial capabilities to offer end-to-end CDMO-type collaboration or white-label opportunities for sponsors seeking streamlined development and faster regulatory approvals.

Financial fit and pace With a modest revenue base and notable funding, pursue opportunities with mid-market pharma companies seeking strategic alliances, co-development, or milestone-driven partnerships that align with Solaris’ scalable manufacturing and cost-efficient timelines.